A monthly recap of the latest news about Alzheimer’s and dementia
FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval
Learn about the new Alzheimer’s drug, Lecanemab, the FDA has approved for treatment. Read more here.
Donanemab in Early Symptomatic Alzheimer Disease
Learn more about the details surrounding donanemab and its results in slowing down Alzheimer’s disease in this recently published study featured in the medical journal JAMA. Read more here.
In older adults at increased risk for cognitive decline, hearing intervention slowed down loss of thinking and memory abilities by 48% over 3 years, according to a new study. Read more here.
Genetic variant specific to African ancestry is associated with increased Alzheimer’s risk
Researchers have found that having a genetic variant observed often in people of African ancestry may increase a person’s risk of developing Alzheimer’s disease. Read more here.
Acumen’s Alzheimer’s drug passes initial safety test
An experimental Alzheimer’s disease drug developed by Acumen Pharmaceuticals targeting a novel form of the toxic protein beta amyloid in the brain passed an early safety test and will advance to a larger trial. Read more here.
CMS proposes broader coverage of PET scans for Alzheimer’s patients
The U.S. Centers for Medicare and Medicaid Services (CMS) on Monday proposed a broader coverage for a type of brain scan, used to identify a key Alzheimer’s disease protein, that will be needed for doctors to determine whether patients are eligible for newly developed drugs. Read more here.
Finger prick blood test could revolutionize Alzheimer’s disease diagnosis, research shows
Research presented for the first time at the Alzheimer’s Association International Conference shows the blood test was more than 80% accurate in identifying changes related to the disease. Read more here.
Changes in human microbiome precede Alzheimer’s cognitive declines
An NIH-funded study elucidates the role of an overlooked and likely culprit that you may not have considered: the human gut microbiome, the trillions of diverse bacteria and other microbes that live primarily in our intestines. Read more here.
The Fight Against Alzheimer’s Is Entering a Critical Phase
Eisai and Biogen’s treatment Leqembi, and a second drug from Eli Lilly & Co. called donanemab, both reduce levels of the amyloid plaques long considered a hallmark of the mind-robbing disease. Read more here.
